Les recommandations de NORML France à la Mission d’Information Cannabis de l’Assemblée Nationale NORML France, par Le Collectif | Avr 20, 2021 | https://www.norml.fr/nos-recommandations-mission-information-cannabis-an/ Nos propositions ont été adressées en février de cette année à la Mission d’information “Réglementation et impact des différents usages du cannabis” de l’Assemblée Nationale. Ce même document de 22 recommandations sera envoyé par email à l’ensemble de nos députés et sénateurs cette semaine. Vous pouvez le retrouver dans sa version complète comme dans sa version courte sur cette page. CANNABIS : VERS UNE RÉGULATION BÉNÉFIQUE AUX USAGERS ET À LA SOCIÉTÉ. 📗 Téléchargez la note complète Cette note est le fruit d’un [...]
Lire la suiteTrial of Psilocybin versus Escitalopram for Depression Robin Carhart-Harris, Ph.D., Bruna Giribaldi, B.Sc., Rosalind Watts, D.Clin.Psy., Michelle Baker-Jones, B.A., Ashleigh Murphy-Beiner, M.Sc., Roberta Murphy, M.D., Jonny Martell, M.D., Allan Blemings, M.Sc., David Erritzoe, M.D. and David J. Nutt, M.D.New England Journal of Medicine, 2021, 384, 1402-1411Doi : 10.1056/NEJMoa2032994 Abstract Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive [...]
Lire la suiteUn grand débat sur une politique de régulation des drogues publié le 19/04/2021 | Communiqué du 19 avril 2021 La Fédération Addiction appelle depuis longtemps à un grand débat sur la régulation des substances psychoactives tant en termes de santé que de sécurité. Le président de la République dresse le constat que « la France est devenue un pays de consommation ». La pénalisation de l’usage de drogues illégales n’a pourtant jamais été remise en cause depuis 51 ans, notre législation reste une des plus sévères et l’application des sanctions n’a cessé de se renforcer. Tout cela est parfaitement documenté par les travaux de l’OFDT et OEDT[1]. Sur la même période, prévention et réduction [...]
Lire la suiteClinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078 Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]
Lire la suiteCannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability Francesca Baratta, Marco Simiele, Irene Pignata, Lorenzo Ravetto Enri, Antonio D’Avolio, Riccardo Torta, Anna De Luca, Massimo Collino and Paola Brusa Pharmaceuticals, 2021, 14, 171, 1-13. Doi : 10.3390/ph14020171 Abstract : Current legislation in Italy provides that medical Cannabis may be administered orally or by inhalation. One of the fundamental criteria for the administration of oral formulations is that they deliver a known consistent quantity of the active ingredients to ensure uniform therapies leading to the optimisation of the risks/benefits. In 2018, our group developed an improved Cannabis oil extraction technique. The objective of [...]
Lire la suiteCannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment Anna Stasiłowicz, Anna Tomala, Irma Podolak and Judyta Cielecka-Piontek International Journal of Molecular Sciences, 2021, 22, 778. Doi : 10.3390/ijms22020778 Abstract : Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results [...]
Lire la suitePotential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain Marta Vázquez, Natalia Guevara, Cecilia Maldonado, Paulo Cáceres Guido, and Paula Schaiquevich Hindawi, BioMed Research International, 2020, Article ID 3902740, 9 pages Doi : 10.1155/2020/3902740 Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between [...]
Lire la suiteCannabinoid Hyperemesis Syndrome : A Case Report and Discussion Regarding Patients with Concurrent Disorders Stephen Lee-Cheong, Amrita Grewal, Lukas Hestvik, Reza Rafizadeh, and Christian Schütz The Canadian Journal of Hospital Pharmacy, 2020, 73, (4), 290-293 INTRODUCTION In October 2018, Canada legalized the nonmedical use of cannabis. Usage has traditionally been high in Canada, and after legalization, self-reported use increased from 14% to 18%.1 Given this increased usage, it is important to understand the adverse effects of cannabis. Here, we focus on a less well-recognized consequence, cannabinoid hyperemesis syndrome (CHS), first described in 2004.2 It may be seen more often in jurisdictions where cannabis is legalized; [...]
Lire la suiteCannabinoids Promising for Improving Appetite, Behavior in Dementia Pauline Anderson Medscape Medical News © March 19, 2021 For patients with dementia, cannabinoids may be a promising intervention for treating neuropsychiatric symptoms (NPS) and the refusing of food, new research suggests. Results of a systematic literature review showed that cannabinoids were associated with reduced agitation, longer sleep, and lower NPS. They were also linked to increased meal consumption and weight gain. Refusing food is a common problem for patients with dementia, often resulting in worsening sleep, agitation, and mood, study investigator Niraj Asthana, MD, a second-year resident in the Department of Psychiatry, University of California, San Diego, told [...]
Lire la suiteAn Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom Jonathan Paul Liebling, Nicholas James Clarkson, Blair William Gibbs, Andrew Stephen Yates, and Saoirse Elizabeth O’Sullivan Cannabis and Cannabinoid Research, 2020, 1-7. DOI: 10.1089/can.2019.0078 Abstract Introduction : Over-the-counter cannabidiol (CBD) products have seen unprecedented recent growth in the United Kingdom. However, analysis of these predominantly unregulated products from other countries tells us that they are often mislabeled or contain unlabeled and potentially dangerous chemicals. Thus, the aim of the present study was to analyze CBD oils available in the United Kingdom. Materials and Methods: Phytocannabinoids, residual solvent, and heavy metals were measured blinded in 29 [...]
Lire la suite